Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating on April 23.
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight Lantheus’ strong commercial presence and promising growth potential. The company is perceived as having a robust long-term growth profile, which is particularly appealing in the current volatile market. Lantheus’ strategic acquisitions in 2025, such as LMI and Evergreen, are expected to enhance its oncology and neuro radiopharma pipeline, which investors are beginning to recognize as a significant value driver.
Additionally, Ruiz anticipates that Lantheus will benefit from potential changes in reimbursement policies for Pylarify, which could lead to increased revenue in 2026. The company’s leadership in PSMA PET imaging, supported by a strong manufacturing and supply chain network, further solidifies its competitive position. Furthermore, the expansion of its pipeline with neuroscience diagnostics and other promising projects like Octevy and PNT2003 adds to the company’s underappreciated potential. These factors collectively contribute to Ruiz’s positive outlook and Buy rating for Lantheus.
According to TipRanks, Ruiz is an analyst with an average return of -15.2% and a 28.04% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Cormedix, Cytokinetics, and United Therapeutics.
In another report released on April 23, TD Cowen also maintained a Buy rating on the stock with a $110.00 price target.